These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8330872)

  • 21. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.
    Gibril F; Reynolds JC; Doppman JL; Chen CC; Venzon DJ; Termanini B; Weber HC; Stewart CA; Jensen RT
    Ann Intern Med; 1996 Jul; 125(1):26-34. PubMed ID: 8644985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma.
    Klutmann S; Bohuslavizki KH; Brenner W; Behnke A; Tietje N; Kröger S; Hugo HH; Mehdorn HM; Clausen M; Henze E
    J Nucl Med; 1998 Nov; 39(11):1913-7. PubMed ID: 9829583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
    Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
    Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
    Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
    Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
    J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
    Giammarile F; Houzard C; Bournaud C; Hafdi Z; Sassolas G; Borson-Chazot F
    Eur J Endocrinol; 2004 Mar; 150(3):277-83. PubMed ID: 15012611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma.
    Klutmann S; Bohuslavizki KH; Tietje N; Kröger S; Behnke A; Brenner W; Mester J; Henze E; Clausen M
    J Nucl Med; 1999 Aug; 40(8):1246-51. PubMed ID: 10450673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI.
    Lee JD; Kim DI; Lee JT; Chang JW; Park CY
    J Nucl Med; 1995 Apr; 36(4):537-41. PubMed ID: 7699438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin receptor scintigraphy in medullary thyroid carcinoma.
    Tisell LE; Ahlman H; Wängberg B; Hansson G; Mölne J; Nilsson O; Lindstedt G; Fjälling M; Forssell-Aronsson E
    Br J Surg; 1997 Apr; 84(4):543-7. PubMed ID: 9112914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
    Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.
    Leboulleux S; Dromain C; Vataire AL; Malka D; Aupérin A; Lumbroso J; Duvillard P; Elias D; Hartl DM; De Baere T; Guigay J; Schlumberger M; Ducreux M; Baudin E
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3021-8. PubMed ID: 18522978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography.
    Bares R; Galonska P; Dempke W; Handt S; Büll U; Osieka R
    Horm Metab Res Suppl; 1993; 27():56-8. PubMed ID: 8330873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome.
    Tsagarakis S; Christoforaki M; Giannopoulou H; Rondogianni F; Housianakou I; Malagari C; Rontogianni D; Bellenis I; Thalassinos N
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4754-8. PubMed ID: 14557451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin receptor imaging in persistent medullary thyroid carcinoma.
    Frank-Raue K; Bihl H; Dörr U; Buhr H; Ziegler R; Raue F
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):31-7. PubMed ID: 7889629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Becker H; Becker W
    Eur J Nucl Med; 1997 Feb; 24(2):184-91. PubMed ID: 9021116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
    Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
    J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
    Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
    Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.
    Dromain C; de Baere T; Lumbroso J; Caillet H; Laplanche A; Boige V; Ducreux M; Duvillard P; Elias D; Schlumberger M; Sigal R; Baudin E
    J Clin Oncol; 2005 Jan; 23(1):70-8. PubMed ID: 15625361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
    Gulec SA; Serafini AN; Sridhar KS; Peker KR; Gupta A; Goodwin WJ; Sfakianakis GN; Moffat FL
    J Nucl Med; 1998 Feb; 39(2):243-5. PubMed ID: 9476928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.
    Koopmans KP; Jager PL; Kema IP; Kerstens MN; Albers F; Dullaart RP
    J Nucl Med; 2008 Aug; 49(8):1232-7. PubMed ID: 18632829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.